These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 21392836)

  • 1. 3-Dimensional reconstruction of a bifurcation lesion with double wire after implantation of a second generation everolimus-eluting bioresorbable vascular scaffold.
    van Geuns RJ; Gogas BD; Farooq V; Regar E; Serruys PW
    Int J Cardiol; 2011 Dec; 153(2):e43-5. PubMed ID: 21392836
    [No Abstract]   [Full Text] [Related]  

  • 2. Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial.
    Onuma Y; Serruys PW; Perkins LE; Okamura T; Gonzalo N; García-García HM; Regar E; Kamberi M; Powers JC; Rapoza R; van Beusekom H; van der Giessen W; Virmani R
    Circulation; 2010 Nov; 122(22):2288-300. PubMed ID: 20975003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three-dimensional reconstruction of the post-dilated ABSORB everolimus-eluting bioresorbable vascular scaffold in a true bifurcation lesion for flow restoration.
    Gogas BD; van Geuns RJ; Farooq V; Regar E; Heo JH; Ligthart J; Serruys PW
    JACC Cardiovasc Interv; 2011 Oct; 4(10):1149-50. PubMed ID: 22017943
    [No Abstract]   [Full Text] [Related]  

  • 4. Optical coherence tomography evaluation of overlapping everolimus-eluting bioresorbable vascular scaffold implantation guided by enhanced stent visualization system.
    Biscaglia S; Secco GG; Tumscitz C; Di Mario C; Campo G
    Int J Cardiol; 2015 Mar; 182():1-3. PubMed ID: 25590956
    [No Abstract]   [Full Text] [Related]  

  • 5. First-in-human description of everolimus-eluting bioabsorbable vascular scaffold implantation for the treatment of drug-eluting stent failure: insights from optical coherence tomography.
    Grasso C; Attizzani GF; Patané M; Ohno Y; Capodanno D; Tamburino C
    Int J Cardiol; 2013 Oct; 168(4):4490-1. PubMed ID: 23890924
    [No Abstract]   [Full Text] [Related]  

  • 6. Bioresorbable polymeric vascular scaffolds: a cautionary tale.
    Ormiston JA; De Vroey F; Serruys PW; Webster MW
    Circ Cardiovasc Interv; 2011 Oct; 4(5):535-8. PubMed ID: 22010192
    [No Abstract]   [Full Text] [Related]  

  • 7. Optimal duration of dual antiplatelet therapy after implantation of bioresorbable vascular scaffolds: lessons from optical coherence tomography.
    Sato K; Panoulas VF; Naganuma T; Miyazaki T; Latib A; Colombo A
    Can J Cardiol; 2014 Nov; 30(11):1460.e15-7. PubMed ID: 25442445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes.
    Serruys PW; Onuma Y; Dudek D; Smits PC; Koolen J; Chevalier B; de Bruyne B; Thuesen L; McClean D; van Geuns RJ; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Hebert KM; Sudhir K; Garcia-Garcia HM; Ormiston JA
    J Am Coll Cardiol; 2011 Oct; 58(15):1578-88. PubMed ID: 21958884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3-D optical coherence tomographic image of bifurcation lesion treated with two Absorb scaffolds.
    Sengottuvelu G; Ligthart JM; Rajendran R
    Indian Heart J; 2015; 67(1):62. PubMed ID: 25820054
    [No Abstract]   [Full Text] [Related]  

  • 10. Three-dimensional optical coherence tomography evaluation of a left main bifurcation lesion treated with ABSORB® bioresorbable vascular scaffold including fenestration and dilatation of the side branch.
    Grundeken MJ; Kraak RP; de Bruin DM; Wykrzykowska JJ
    Int J Cardiol; 2013 Oct; 168(3):e107-8. PubMed ID: 23972365
    [No Abstract]   [Full Text] [Related]  

  • 11. One-Year Coverage by Optical Coherence Tomography of a Bioresorbable Scaffold Neocarina: Is It Safe to Discontinue Dual-Antiplatelet Therapy?
    Capranzano P; Francaviglia B; Tamburino CI; Gargiulo G; Longo G; Capodanno D; Tamburino C
    Can J Cardiol; 2015 Sep; 31(9):1205.e5-6. PubMed ID: 26118449
    [No Abstract]   [Full Text] [Related]  

  • 12. Incomplete arterial healing 8 years after the implantation of sirolimus-eluting stent. In vivo visualization by optical coherence tomography.
    Bouki KP; Sakkali EK; Apostolou TS
    Catheter Cardiovasc Interv; 2012 Mar; 79(4):625-7. PubMed ID: 21735524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spatial distribution of neo-intimal hyperplasia 6 months after zotarolimus-eluting stent implantation, analysed by optical coherence tomography.
    Souteyrand G; Levesque S; Ouchchane L; Sarry L; Eschalier R; Lusson JR; Motreff P
    Arch Cardiovasc Dis; 2011 Mar; 104(3):147-54. PubMed ID: 21497303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optical coherence tomography (OCT) of overlapping bioresorbable scaffolds: from benchwork to clinical application.
    Farooq V; Onuma Y; Radu M; Okamura T; Gomez-Lara J; Brugaletta S; Gogas BD; van Geuns RJ; Regar E; Schultz C; Windecker S; Lefèvre T; Brueren BR; Powers J; Perkins LL; Rapoza RJ; Virmani R; García-García HM; Serruys PW
    EuroIntervention; 2011 Jul; 7(3):386-99. PubMed ID: 21729842
    [No Abstract]   [Full Text] [Related]  

  • 15. Novel neointimal formation over sirolimus-eluting stents identified by coronary angioscopy and optical coherence tomography.
    Murakami D; Takano M; Yamamoto M; Inami S; Ohba T; Seino Y; Mizuno K
    J Cardiol; 2009 Apr; 53(2):311-3. PubMed ID: 19304139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Late vascular responses from 2 to 4 years after implantation of sirolimus-eluting stents: serial observations by intracoronary optical coherence tomography.
    Takano M; Yamamoto M; Mizuno M; Murakami D; Inami T; Kimata N; Murai K; Kobayashi N; Okamatsu K; Ohba T; Seino Y; Mizuno K
    Circ Cardiovasc Interv; 2010 Oct; 3(5):476-83. PubMed ID: 20823394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ComparisOn of neointimal coVerage betwEen zotaRolimus-eluting stent and everolimus-eluting stent using Optical Coherence Tomography (COVER OCT).
    Kim JS; Kim BK; Jang IK; Shin DH; Ko YG; Choi D; Hong MK; Cho YK; Nam CW; Hur SH; Choi JH; Song YB; Hahn JY; Choi SH; Gwon HC; Jang Y
    Am Heart J; 2012 Apr; 163(4):601-7. PubMed ID: 22520526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe intimal hyperplasia after sirolimus eluting stent deployment: evaluation by optical coherence tomography.
    Gupta R; Raffel OC; Jang IK
    Heart; 2007 Jun; 93(6):754. PubMed ID: 17502657
    [No Abstract]   [Full Text] [Related]  

  • 19. Vascular response to a third generation everolimus-eluting stent.
    Wilson GJ; Huibregtse BA; Stejskal EA; Crary J; Starzyk RM; Dawkins KD; Barry JJ
    EuroIntervention; 2010 Sep; 6(4):512-9. PubMed ID: 20884440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective randomised study using optical coherence tomography to assess endothelial coverage and neointimal proliferation at 6-months after implantation of a coronary everolimus-eluting stent compared with a bare metal stent postdilated with a paclitaxel-eluting balloon (OCTOPUS Trial): rationale, design and methods.
    Poerner TC; Otto S; Gassdorf J; Janiak F; Danzer C; Ferrari M; Figulla HR
    EuroIntervention; 2011 May; 7 Suppl K():K93-9. PubMed ID: 22027737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.